Cargando…

What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling

INTRODUCTION: There is a critical need to understand the optimal treatment regimen in patients with potentially resectable stage III-N2 nonsmall cell lung cancer (NSCLC). METHODS: A systematic review of randomised controlled trials was carried out using a literature search including the CDSR, CENTRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evison, Matthew, Maconachie, Ross, Mercer, Toby, Daly, Caitlin H., Welton, Nicky J., Aslam, Shahzeena, West, Doug, Navani, Neal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068518/ https://www.ncbi.nlm.nih.gov/pubmed/37020838 http://dx.doi.org/10.1183/23120541.00299-2022

Ejemplares similares

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
por: Lee, Jay M., et al.
Publicado: (2023)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
por: Perrotta, Fabio, et al.
Publicado: (2019)

How should performance in EBUS mediastinal staging in lung cancer be measured?
por: Evison, Matthew, et al.
Publicado: (2016)

Development and validation of machine learning models to predict survival of patients with resected stage-III NSCLC
por: Jin, Long, et al.
Publicado: (2023)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Long-Term Recurrence of Completely Resected NSCLC
por: Masago, Katsuhiro, et al.
Publicado: (2020)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Advanced fixed point theory for economics
por: McLennan, Andrew
Publicado: (2018)

Advanced fixed point theory for economics /
por: McLennan, Andrew
Publicado: (2018)

Update on adjuvant therapy in completely resected NSCLC patients
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC
por: Antonoff, Mara B., et al.
Publicado: (2022)

The impact of the Covid-19 pandemic on lung cancer incidence in England: an analysis of the 2019 and 2020 Rapid Cancer Registration Datasets
por: Gysling, Savannah, et al.
Publicado: (2022)

Pulmonary resection for NSCLC in octogenarians: a single center experience
por: Di Russo, S, et al.
Publicado: (2011)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Donington, Jessica S.
Publicado: (2021)

Cost‐effectiveness of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris
por: Mavranezouli, Ifigeneia, et al.
Publicado: (2022)

The impact of COVID-19 on lung cancer diagnostics – a multicentre comparison of 2019/2020 data
por: Navani, Neal, et al.
Publicado: (2021)

Quantifying the impact of Covid-19 on lung cancer: an urgent need for restoration
por: O’Dowd, Emma, et al.
Publicado: (2021)

Scalable, economical, and stable sequestration of agricultural fixed carbon
por: Yablonovitch, Eli, et al.
Publicado: (2023)

Evaluate the outcome of pneumonectomy for stage III a-N2 NSCLC
por: Park, Sungjoon, et al.
Publicado: (2015)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
por: Gibson, Amanda J.W., et al.
Publicado: (2023)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
por: Borghetti, Paolo, et al.
Publicado: (2022)

Assessing the consistency assumptions underlying network meta‐regression using aggregate data
por: Donegan, Sarah, et al.
Publicado: (2018)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
por: Graham, Donna M., et al.
Publicado: (2014)

Hitting a HOMER: Epidemiology to the Bedside when Evaluating for Stereotactic Ablative Radiotherapy
por: DiBardino, David M., et al.
Publicado: (2020)

Tracheo-parenchymal fistula following concurrent chemo-radiation for stage III NSCLC
por: Alzghoul, Bashar, et al.
Publicado: (2016)

Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
por: Iseli, Thomas, et al.
Publicado: (2020)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC
por: Yu, Hongliang, et al.
Publicado: (2020)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
por: Lee, Jay M., et al.
Publicado: (2021)

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021)

Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers
por: Ruel, Louis-Jacques, et al.
Publicado: (2022)

The Effect of Lung Resection for NSCLC on Circulating Immune Cells: A Pilot Study
por: Phillips, Joseph D., et al.
Publicado: (2023)

Occult lymph node metastasis is not a favorable factor for resected NSCLC patients
por: Cai, Jing-Sheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3sti1h62mcvmadju4k9tohgi2o